Internal No Sidebar

Lorem ipsum dolor sit amet, et unum docendi nam (h1)

Lorem ipsum dolor sit amet, et unum docendi nam, ea mei iriure insolens, nec te prima invenire. At brute lorem adolescens usu, vis ne clita alterum. Dicta animal facilisi duo cu. Ridens pertinax conceptam eam ex. Eum no dicant melius definitionem, duo ne vero molestie invidunt.

Mei qualisque adolescens reprimique ea, sit tempor invenire at. Id atqui aliquip mel, ei tibique minimum eum, ex pri aliquip persecuti appellantur. Nulla conclusionemque eos ei, et usu animal integre volumus, quidam suscipit molestiae eos ea. Nec soleat concludaturque ea, quodsi dolores suavitate sed at, ea alia sonet elitr duo. Fabellas adolescens pro ea. Quot lorem dicam pri ex, qui an tritani perfecto.

Nonumy impedit reprehendunt (h2)

Ut copiosae signiferumque sed, pri ad alii debitis prodesset, vis ea elit augue volumus. Nonumy impedit reprehendunt vel cu, illud audiam nec ne. Et nec nisl libris, nec ex aperiri oportere temporibus, quo nihil numquam ut. Eu habemus deleniti singulis duo. Mei melius intellegam ad.

Mea clita ceteros reprehendunt ad, et mei docendi recteque, nec sa.

No ignota aperiri vim, ius no alii omnes nostrud. Dicam mnesarchum ad pro, vel ne zril inermis. Adhuc utinam ne ius, ius ea inimicus definitionem. Ea vix audire malorum, mei in facilis scriptorem. Alia constituam ea sed, cu cum noster assueverit. Eum timeam erroribus constituam eu, eripuit voluptatum quaerendum eu ius, ne munere ancillae maluisset sit.

Mea clita ceteros reprehendunt ad (h3)

Ut wisi ceteros has, porro noster facilisis (h4)

  • Mea clita ceteros reprehendunt ad
  • Et mei docendi recteque
  • Nec saepe malorum quaerendum ei.

Button Style 1

Button Style 2

Lorem Ipsum Video Caption
Lorem Ipsum Video Caption
Personnel Placeholder
Lorem ipsum dolor sit amet, pri id fugit contentiones, eam putant laboramus in, ex ius alia nibh conclusionemque. Id eum mundi nonumes, nec oratio tincidunt forensibus et. Justo dicit equidem cu vel. Ex maiorum vituperatoribus vim. Usu appetere prodesset ut, mei no justo minim aliquam. Et ius everti scripserit.
Jane Doe - Charleston, SC

Content with Accordion

Taysha Announces First Patient Dosed with Gene Therapy

Monday, June 5, 2023

A First in Rett Syndrome! Taysha Gene Therapies announced today that the first Rett syndrome patient has been dosed with the investigational gene therapy, TSHA-102, in a clinical trial for females 18 and older being run out of Montreal, Canada. Read their press release and full community update below. ———————- June 5, 2023 Dear Rett … Read More

A First for Rett: FDA Approves Trofinetide for Treatment of Rett Syndrome!

Friday, March 10, 2023

This first-ever treatment is approved for individuals with Rett syndrome. (Updated March 19, 2023) On March 10, 2023, Acadia Pharmaceuticals announced that their investigational drug, Trofinetide, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of Rett syndrome. The drug, marketed under the name DAYBUE™, is expected to be commercially … Read More

IRSF Establishes Research Fund for Males with Rett Syndrome

Tuesday, February 21, 2023

The fund is established thanks to an inaugural gift from the Otis Family in honor of their son, Barrett. The Rett syndrome research landscape has never been more exciting. New clinical trials are underway in gene therapy, and we eagerly await the FDA’s decision about Trofinetide. But we know that families of males with Rett … Read More

Taysha Gene Therapies Provides Update on Expansion of TSHA-102 Study

Wednesday, February 1, 2023

READ TAYSHA’S LETTER TO THE RETT COMMUNITY DALLAS, Jan. 31, 2023 (GLOBE NEWSWIRE) — Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical -stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic rare diseases of the central nervous system (CNS), today provided an update on the TSHA-120 program in giant axonal … Read More

IRSF Awards $4.4M in Rett Syndrome Research Grants

Tuesday, January 31, 2023

Our commitment to setting up the next wave of Rett breakthroughs continues with the largest annual investment in our Foundation’s history. By Dr. Dominique Pichard, IRSF Chief Science Officer We are entering new territory for Rett syndrome. Right now, the FDA is evaluating the first-ever potential treatment specifically targeting Rett syndrome, trofinetide. No potential treatment … Read More

Callout Button Callout Button

Two Equal Columns of Text

Lorem ipsum dolor sit amet, et unum docendi nam, ea mei iriure insolens, nec te prima invenire. At brute lorem adolescens usu, vis ne clita alterum. Dicta animal facilisi duo cu. Ridens pertinax conceptam eam ex. Eum no dicant melius definitionem, duo ne vero molestie invidunt.

Mei qualisque adolescens reprimique ea, sit tempor invenire at. Id atqui aliquip mel, ei tibique minimum eum, ex pri aliquip persecuti appellantur. Nulla conclusionemque eos ei, et usu animal integre volumus, quidam suscipit molestiae eos ea. Nec soleat concludaturque ea, quodsi dolores suavitate sed at, ea alia sonet elitr duo. Fabellas adolescens pro ea. Quot lorem dicam pri ex, qui an tritani perfecto.

Ut copiosae signiferumque sed, pri ad alii debitis prodesset, vis ea elit augue volumus. Nonumy impedit reprehendunt vel cu, illud audiam nec ne. Et nec nisl libris, nec ex aperiri oportere temporibus, quo nihil numquam ut. Eu habemus deleniti singulis duo. Mei melius intellegam ad.

Ut nec modus option, ex est maiestatis contentiones disputationi. Pri in vidit definiebas, ex eum vivendo consulatu, cu mundi nostrud pertinax eam. Nec timeam fabellas no, idque audire nec ea. Mel an modo magna minimum, at posse invidunt mea. Ius no doctus patrioque, dicam legere dissentias qui ea. Mel ei solum ullum fastidii, sit eius brute doctus eu.

Mea clita ceteros reprehendunt ad, et mei docendi recteque, nec saepe malorum quaerendum ei. Ut wisi ceteros has, porro noster facilisis ex nam, hinc tantas ea eos. Persius eruditi ut mea, graecis salutatus conclusionemque id pro. Eu nec graeci aliquip. Eos ex esse lorem alterum, et utinam putent mei, ei imperdiet cotidieque vim. Fierent honestatis eu his, cu consequat assueverit has, justo nihil referrentur cu eam.

Content with Tabs

Mea clita ceteros reprehendunt ad, et mei docendi recteque, nec saepe malorum quaerendum ei. Ut wisi ceteros has, porro noster facilisis ex nam, hinc tantas ea eos. Persius eruditi ut mea, graecis salutatus conclusionemque id pro. Eu nec graeci aliquip. Eos ex esse lorem alterum, et utinam putent mei, ei imperdiet cotidieque vim. Fierent honestatis eu his, cu consequat assueverit has, justo nihil referrentur cu eam.

Mea clita ceteros reprehendunt ad, et mei docendi recteque, nec saepe malorum quaerendum ei. Ut wisi ceteros has, porro noster facilisis ex nam, hinc tantas ea eos. Persius eruditi ut mea, graecis salutatus conclusionemque id pro. Eu nec graeci aliquip. Eos ex esse lorem alterum, et utinam putent mei, ei imperdiet cotidieque vim. Fierent honestatis eu his, cu consequat assueverit has, justo nihil referrentur cu eam.

Mea clita ceteros reprehendunt ad, et mei docendi recteque, nec saepe malorum quaerendum ei. Ut wisi ceteros has, porro noster facilisis ex nam, hinc tantas ea eos. Persius eruditi ut mea, graecis salutatus conclusionemque id pro. Eu nec graeci aliquip. Eos ex esse lorem alterum, et utinam putent mei, ei imperdiet cotidieque vim. Fierent honestatis eu his, cu consequat assueverit has, justo nihil referrentur cu eam.

Simple Data Table

unum docendiunum docendiunum docendi
Lorem ipsum dolor sit amet, et unum docendi namLorem ipsum dolor sit amet, et unum docendi namLorem ipsum dolor sit amet, et unum docendi nam
Lorem ipsum dolor sit amet, et unum docendi namLorem ipsum dolor sit amet, et unum docendi namLorem ipsum dolor sit amet, et unum docendi nam
Lorem ipsum dolor sit amet, et unum docendi namLorem ipsum dolor sit amet, et unum docendi namLorem ipsum dolor sit amet, et unum docendi nam

Personnel Module

John Doe

CFP

Lorem ipsum dolor sit amet, et unum docendi nam, ea mei iriure insolens, nec te prima invenire. At brute lorem adolescens usu, vis ne clita alterum. Dicta animal facilisi duo cu. Ridens pertinax conceptam eam ex. Eum no dicant melius definitionem, du

Email John

Jane Doe

CEO

Lorem ipsum dolor sit amet, et unum docendi nam, ea mei iriure insolens, nec te prima invenire. At brute lorem adolescens usu, vis ne clita alterum. Dicta animal facilisi duo cu. Ridens pertinax conceptam eam ex.

Email Jane

Riley Smith

Developer

Lorem ipsum dolor sit amet, et unum docendi nam, ea mei iriure insolens, nec te prima invenire. At brute lorem adolescens usu, vis ne clita alterum. Dicta animal facilisi duo cu. Ridens pertinax conceptam eam ex. Eum no dicant melius definitionem, du

Email Riley